

# Risperidone 유발 지연성 운동장애 一例

김헌수\*<sup>†</sup> · 김현실\*\* · 민병근\*\*\*

## A Case on Risperidone-Induced Tardive Dyskinesia

Hun-Soo Kim, M.D.,\*<sup>†</sup> Hyun-Sil Kim, Ph.D.,\*\* Byung-Kun Min, M.D.\*\*\*

### ABSTRACT

**Objective** : Base on clinical practice, the authors report a case of tardive dyskinesia arising during the course of treatment with risperidol.

**Methods** : This article was review and analysis of a case on risperidone-induced tardive dyskinea.

**Results** : Mrs K, a 51-year-old woman with a 1-year history of schizophrenic disorder, gradually developed tardive dyskinetic movement of the mouth, lip, and tongue over a 4 month period(From July, 1996 to June, 1997) while taking risperidone. Initially she was treated with haloperidol and alprazolam. However, the haloperidol was subsequently discontinued because of EPS developed. From 11th March, 1997, she was observed to have a severe form of tardive dyskinesia involving her tongue, lip, and mouth. After risperidone was withdrawn at 9th May 1997, her tardive dyskinetic movement was disappeared.

**Conclusions** : This is, to our knowledge, the first report of the onset of tardive dyskinesia in a patient taking risperidone. However, additional controlled studies of specific questions are needed ; e.g., the dose-response curves for produce tardive dyskinesia and the mechanism of producing risperidone-induced tardive dyskinea and so on.

**KEY WORDS** : Risperidone · Tardive dyskinesia.

### 서 론

Risperidone 1994 Janssen  
benzisoaxazol  
5-HT<sub>2</sub>, D<sub>2</sub>  
(tardive dyskinesia) 가

(Borison 1992 ; Chouinard Arnott 1993) risperi-  
done risperidone

### Risperidone의 약리학적 특성

1. 특 징  
Risperidone dopamine(D<sub>2</sub>) serotonin(5-HT)  
benzisoaxazol (Le -  
ysen 1988). 가 neuroleptics ri -  
speridone hyperdopaminergic D<sub>2</sub> activity  
가  
5-HT<sub>2</sub>, risperidone  
tryptamine

Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Department of Nursing, Kyungsan University, Kyungsan, Korea

Department of Psychiatry, Keyo Hospital, Uiwang, Kyungkido, Korea

\* : 138 - 736 388 - 1  
(02) 224 - 3413, (02) 485 - 8381

mescaline - hydroxytryptophan 5 - hydroxytr - (Chouinard 1993 ;  
 yptophan 肥滿細胞(mast cell) Mok Yatham 1994).  
 1988). (Janssen Risperidone 1 adren -  
 D<sub>2</sub> histamine H<sub>1</sub> adrenergic 2 (Sleight 1993),  
 Risperidone cholinergic muscarinic receptor dopa -  
 (Matsubara 1993). clozapine ris - mine D<sub>1</sub> receptor  
 peridone .  
 1992). (Borison 2. 약물역동  
 Benzisoxazol Risperidone D<sub>2</sub> Risperidone 1  
 , 5HT<sub>2</sub> 가  
 (Ereshefsky Lacombe 1993 ; Roth 1992). Risperidone 9 - hydroxyrisperidon  
 가 Risperidone (9 - hydroxyrisperidone)  
 24 (Land Salzman 1994).  
 (Matthyse 1977). chlorproma - Huang (1993) risperidone  
 L - dopa가 (extensive metabolizers : 3 ) (poor  
 (Yaryura - Tobias 1970), 가가 metabolizers : 22 )  
 가 가 .  
 D<sub>2</sub> (hyperdopaminergic D<sub>2</sub> 3. 효 능  
 disorder) (Remi - risperidone  
 ngton 1993). (Addington 1993 ;  
 가 risperidone antiserotonergic drug Chouinard Arnott 1993 ; Remington 1993).  
 1954 Woolley Shaw가 Chouinard (1993) risperidone .  
 (5HT<sub>2</sub>) (D<sub>2</sub>) , Borison (1992) risperid -  
 one haloperidol  
 .  
 5HT<sub>2</sub> eridone  
 , D<sub>2</sub> haloperidol 가  
 (Chouinard 1993 ; Marder 1992).  
 (Ereshefsky Lacombe 1993). 4. 투여방법  
 Risperidone 2가 Marder Meibach(1994) 1 6mg  
 risperidone neuroleptics 가 risperidone 가 .  
 , , , (Mannens 1993).  
 , Risperidone 1mg 2 ,  
 ( , , ) 2mg 2 , 3 3mg 2  
 (Awouters 1990 ; Bori -  
 son 1992 ; Brown 1993). 5. 부작용  
 Risperidone Risperidone muscarin

Risperidone  
(Chouinard Arnott 1993 ; Land Salzman 1994 ;  
Meltzer 1993).

1996 7

Clozapine risperidone  
(Edwards 1994),  
가 (Bezchlibnyk -  
Butler Remington 1994 ; Marder Meibach 1994).

2 가

risperidone

가

가

가 가

(Borison 1992 ; Chouinard

가

2

Arnott 1993).

risperidone

2

가

2

2

### 증 례

#### 3. 치료 및 경과

#### 1. 개인력

51

1996 7 9

1996 7

alprazolam(0.25mg 3T

가

# 3), halcion(0.5mg hs)

3

7 12

haloperidol(0.5mg 3T # 3)

가

가 1 2

7 19

haloperidol

risperidone 1mg

가

가

가

가 27

1 2

8 2

risperidone(3mg 2T

# 2)

8 16

haloperidol

risperidone 1.5mg 0.5T( ), 3mg 1T( )

9

가

24

가

1997 3 11

(bucco -

#### 2. 진찰소견 및 정신상태

linguomasticatory tardive dyskinesia)

( : 163cm, : 61kg),



## 참고문헌

- Addington D, Jones B, Bloom D, Chouinard G, Albright P(1993)** : Reduction of hospital days in chronic schizophrenic patients treated with risperidone : A retrospective study. *Clin Ther* 15 : 917-926
- Aouters F, Niemegeers C, Megens A, Janssen P(1990)** : Functional interaction between serotonin-5<sub>2</sub> and dopamine-D<sub>2</sub> neurotransmission as revealed by selective antagonism of hyperreactivity to tryptamine and apomorphine. *J Pharmacol Exp Ther* 254 : 945-951
- Bezchlibnyk-Butler K, Remington G(1994)** : Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. *Can J Psychiatry* 39 : 74-84
- Borison R, Pathiraja A, Diamond B, Meibach R(1992)** : Risperidone : Clinical safety and efficacy in schizophrenia. *Psychopharmacol Bull* 28 : 213-218
- Brown K, Levy H, Brenner C, Leffler S, Hamburg E(1993)** : Overdose of risperidone. *Ann of Emerg Med* 22 : 140-142
- Chouinard G, Arnott W(1993)** : Clinical review of risperidone. *Can J Psychiatry* 38 : S89-S95
- Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwen G, Labelle A, Beauclair L, Arnott W(1993)** : A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol* 13 : 25-40
- Edward J(1994)** : Risperidone for schizophrenia. *BMJ* 308 : 1311-1312
- Ereshefsky L, Lacombe S(1993)** : Pharmacological profile of risperidone. *Can J of Psychiatry* 38 : S80-S88
- Feeney DJ, Klykylo W(1996)** : Risperidone and tardive dyskinesia. *J Am Acad Child Adolesc Psychiatry* 35 : 1421-1422
- Huang M, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen A, Zyllicz Z, Visscher H, Jonkman J(1993)** : Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. *Clin Pharmacol Ther* 54 : 257-268
- Janssen PAJ, Niemegeers CJE, Aouters F, et al(1988)** : Pharmacology of risperidone (R 66 766), a new antipsychotic with serotonin-D<sub>2</sub> and dopamine-D<sub>2</sub> antagonistic properties. *J Pharmacol Exp Ther* 244 : 685-693
- Keltner NL(1995)** : Risperidone : The search for a better antipsychotic. *Perspectives in Psychiatric Care* 31 : 30-33
- Land W, Salzman C(1994)** : Risperidone : A novel antipsychotic medication. *Hosp Community Psychiatry* 45 : 434-435
- Leysen JE, Gommeren W, Eens A, et al(1988)** : Biochemical profile of risperidone, a new antipsychotic. *J Pharmacol Exp Ther* 247 : 661-670
- Mannens G, Huang M, Meuldermans W, Hendrick J, Woestenborghs R, Heykants J(1993)** : Absorption, metabolism, and excretion of risperidone in humans. *Drug Metab Dispos* 21 : 1134-1141
- Marder S(1992)** : Risperidone : Clinical development : North American results. *Clin Neuropharmacol* 15 : 92A-93A
- Marder S, Meibach R(1994)** : Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 151 : 825-835
- Matsubara S, Matsubara R, Kusumi I, Kogama T, Yamashita I(1993)** : Dopamine D<sub>1</sub>, D<sub>2</sub> and serotonin D<sub>2</sub> receptor occupation by typical and atypical antipsychotic drugs in vivo. *J Pharmacol Exp Ther* 265 : 498-508
- Matthysse S(1977)** : The role of dopamine in schizophrenia, In : *Neuroregulators and Psychiatric disorders*. Ed by Usdin E, Hamburg D, Barchas J, New York, Oxford University Press, 3-13
- Meltzer H(1993)** : New drugs for the treatment of schizophrenia. *Psychiatr Clin North Am* 16 : 365-385
- Mok H, Yatham L(1994)** : Response to clozapine as a predictor of risperidone response in schizophrenia (letter). *Am J Psychiatry* 151 : 1393-1394
- Remington GJ(1993)** : Clinical considerations in the use of risperidone. *Can J Psychiatry* 38 : S96-S100
- Roth R, Ciaranello R, Meltzer H(1992)** : Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT-1c receptors. *J Pharmacol Exp Ther* 260 : 1361-1365
- Sleight A, Koek W, Bigg D(1993)** : Binding of antipsychotic drugs at alpha-1A and alpha-1B adrenoreceptors : Risperidone is selective for the alpha-1B adrenoreceptors. *Eur J Pharmacol* 238 : 407-410
- Yaryura-Tobias Y, Diamond B, Meris S(1970)** : The actions of L-dopa on schizophrenic patients (a preliminary report). *Current Therapeutic Research* 12 : 528-531